Sanofi is reportedly mulling a takeover bid for respiratory disease-focused biotech Insmed as the company approaches an M&A-heavy dealmaking strategy under its new CEO Belén Garijo.
As per Bloomberg, which first reported the news, the French pharmaceutical giant is currently in talks with its advisers, which could lead to a deal that sources say may become the largest of its kind since Pfizer’s $43bn Seagen acquisition in 2023.
Discover B2B Marketing That Performs
Combine business intelligence and editorial excellence to reach engaged professionals across 36 leading media platforms.
Insmed declined to provide comment, while Sanofi did not immediately respond when approached by Pharmaceutical Technology.
If the deal goes through, Sanofi would absorb the rights to Insmed’s portfolio of respiratory medicines, which includes non-cystic fibrosis bronchiectasis (NCFB) therapy, Brinsupri (brensocatib) and refractory Mycobacterium avium complex (MAC) lung disease drug, Arikayce (amikacin liposome inhalation suspension). The company would also secure access to Insmed’s pipeline, which includes a range of clinical and preclinical medicines for a variety of lung conditions, such as chronic obstructive pulmonary disease (COPD) and idiopathic pulmonary fibrosis (IPF).
According to head biotech equity research analyst at William Blair, Matt Phipps, Sanofi has been seen as a “rational fit” for Insmed due to their overlapping respiratory franchises.
“We believe it particularly makes sense in light of the commercial push into COPD with the recent Dupixent approval,” Phipps commented in a research note. However, he did question whether Sanofi has the capacity for this deal, and the price that Insmed would be willing to sell at.
The reported deal comes as Sanofi looks to fortify its pipeline and portfolio amid the looming patent expiry of its blockbuster respiratory drug Dupixent (dupilumab), which is slated to lose its US market exclusivity in 2031. In Q3 2026, Dupixent’s sales ballooned by nearly 35% to reach €5.7bn ($6.2bn).
At the time of the Q3 results debut, Sanofi’s CFO, Francois Roger, noted that the French pharma is increasingly eyeing larger deals centred around late-stage investigational or marketed products – primarily in the areas in which it is known, including vaccines, immunology and rare diseases.
According to a research note from Jefferies’ European pharma and biotech lead, Michael Leuchten, these areas of focus are a “good strategic fit” for Sanofi, and M&A will play a key role in bolstering Sanofi’s outlook as Dupixent’s loss of exclusivity nears.
This change in tack comes as Garijo – prior CEO of Merck KGaA – looks to set Sanofi up for future growth. She has also promised investors that she will speed up decision-making within the company.
Garijo took the helm at Sanofi in May after prior CEO Paul Hudson was ousted following a string of high-profile clinical trial failures.
